US to pull out from Paris Agreement that limits global warmingÂ
The US, the worldâs second-largest greenhouse gas emitter in the world, will withdraw from a global pact to limit global warming.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
The US, the worldâs second-largest greenhouse gas emitter in the world, will withdraw from a global pact to limit global warming.
The US, the World Health Organizationâs top donor, has decided to withdraw from the global health body, accusing it of âmishandlingâ the Covid-19.
HQ Team January 20, 2024:People with fat stored within their muscles, known as intermuscular fat, face a significantly higher risk of serious cardiovascular.
HQ Team January 20, 2025: Research has unveiled 293 new gene variants linked to major depressive disorder (MDD), significantly enhancing our understanding of.
HQ Team January 19, 2025: A study led by researchers from the Broad Institute, Harvard Medical School, and McLean Hospital has shed light.
AstraZeneca Plc.âs antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
HQ Team January 17, 2025: The commonly prescribed sleep medications, particularly zolpidem, known by its brand name Ambien, may disrupt the brain’s natural.
HQ Team January 17, 2025: A study has found a significant association between the use of hormonal contraceptives and an increased risk of.
Atara Biotherapeuticsâ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.
HQ Team The US Food and Drug Administration (FDA) has approved Eli Lillyâs Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active.